Loading
A Chinese study developing a blood test for several gynaecological cancers at once.
PERCEIVE-I (NCT04903665) is an observational study sponsored by Fudan University with Guangzhou Burning Rock Bioengineering Ltd. It develops and validates combined cell-free DNA methylation, mutation and microRNA assays for early detection of gynaecological cancers.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 28 July 2022), with 495 participants enrolled, a start on 11 February 2021 and primary completion expected on 22 August 2022.
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/